Close Menu

NEW YORK (GenomeWeb) – Cancer diagnostics firm Oncimmune said today that it has acquired Protagen Diagnostics for up to £4.1 million ($5.5 million).

The final price is subject to performance milestones and will be paid in Oncimmune shares issued at 156p ($2.07) per share, which it said was a premium of 71 percent over its closing price on March 18, 2019.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.